{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:14:26Z","timestamp":1775225666936,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vaccine.2021.12.043","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T17:53:05Z","timestamp":1640800385000},"page":"934-944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models"],"prefix":"10.1016","volume":"40","author":[{"given":"Eirikur","family":"Saeland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"van der Fits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renske","family":"Bolder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"Heemskerk-van der Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joke","family":"Drijver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolinda","family":"van Polanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Vaneman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisanne","family":"Tettero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Callendret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes P.M.","family":"Langedijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland C.","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.vaccine.2021.12.043_b0005","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.043_b0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/CMR.13.3.371","article-title":"Respiratory syncytial virus infection in adults","volume":"13","author":"Falsey","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"9725","key":"10.1016\/j.vaccine.2021.12.043_b0015","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.12.043_b0020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fimmu.2014.00466","article-title":"Immunity to RSV in early-life","volume":"5","author":"Lambert","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.12.043_b0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coviro.2016.01.003","article-title":"Determinants of early life immune responses to RSV infection","volume":"16","author":"Ruckwardt","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.043_b0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.immuni.2019.08.007","article-title":"Immunological lessons from respiratory syncytial virus vaccine development","volume":"51","author":"Ruckwardt","year":"2019","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.vaccine.2021.12.043_b0035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2021.12.043_b0040","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/14760584.2019.1675520","article-title":"Vaccines against human respiratory syncytial virus in clinical trials, where are we now?","volume":"18","author":"Rossey","year":"2019","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2021.12.043_b0045","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2021.12.043_b0050","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0264-410X(89)90278-8","article-title":"Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease","volume":"7","author":"Murphy","year":"1989","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.043_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.13.1.1","article-title":"Respiratory syncytial virus genetic and antigenic diversity","volume":"13","author":"Sullender","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"21","key":"10.1016\/j.vaccine.2021.12.043_b0060","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJM199311183292102","article-title":"Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group","volume":"329","author":"Groothuis","year":"1993","journal-title":"N Engl J Med"},{"issue":"309","key":"10.1016\/j.vaccine.2021.12.043_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"issue":"6452","key":"10.1016\/j.vaccine.2021.12.043_b0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.043_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat Commun"},{"issue":"6136","key":"10.1016\/j.vaccine.2021.12.043_b0080","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.043_b0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01092-4","article-title":"Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV","volume":"8","author":"Steff","year":"2017","journal-title":"Nat Commun"},{"issue":"32","key":"10.1016\/j.vaccine.2021.12.043_b0090","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.043_b0095","doi-asserted-by":"crossref","first-page":"e0174728","DOI":"10.1371\/journal.pone.0174728","article-title":"Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform","volume":"12","author":"Salisch","year":"2017","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.043_b0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-0200-y","article-title":"Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice","volume":"5","author":"van der Fits","year":"2020","journal-title":"npj Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2021.12.043_b0105","doi-asserted-by":"crossref","first-page":"e44115","DOI":"10.1371\/journal.pone.0044115","article-title":"Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species","volume":"7","author":"Zahn","year":"2012","journal-title":"PLoS ONE"},{"issue":"44","key":"10.1016\/j.vaccine.2021.12.043_b0110","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1016\/j.vaccine.2009.07.106","article-title":"Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys","volume":"27","author":"Rodr\u00edguez","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.043_b0115","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged >\/=60 Years","volume":"222","author":"Williams","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.12.043_b0120","article-title":"Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study","author":"Sadoff","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.12.043_b0125","doi-asserted-by":"crossref","unstructured":"Sadoff J, De Paepe E, Haazen W, Omoruyi E, Bastian AR, Comeaux C, et al. Safety and Immunogenicity of the Ad26.RSV.preF investigational vaccine coadministered with an influenza vaccine in older adults. J Infect Dis. 2021;223:699\u2013708.","DOI":"10.1093\/infdis\/jiaa409"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.043_b0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.virol.2012.09.022","article-title":"A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis","volume":"434","author":"Hotard","year":"2012","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.043_b0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nprot.2014.005","article-title":"Intravascular staining for discrimination of vascular and tissue leukocytes","volume":"9","author":"Anderson","year":"2014","journal-title":"Nat Protoc"},{"issue":"41","key":"10.1016\/j.vaccine.2021.12.043_b0140","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.12.043_b0145","doi-asserted-by":"crossref","first-page":"e69390","DOI":"10.1371\/journal.pone.0069390","article-title":"Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity","volume":"8","author":"Gupta","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.12.043_b0150","first-page":"19","article-title":"Human antibody-dependent cell-mediated cytotoxicity against target cells infected with respiratory syncytial virus","volume":"28","author":"Scott","year":"1977","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2021.12.043_b0155","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.4049\/jimmunol.122.6.2521","article-title":"Antibody-dependent cell-mediated cytotoxicity against cells infected with respiratory syncytial virus: characterization of in vitro and in vivo properties","volume":"122","author":"Meguro","year":"1979","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.12.043_b0160","article-title":"Natural killer cell activation by respiratory syncytial virus-specific antibodies is decreased in infants with severe respiratory infections and correlates with Fc-glycosylation","volume":"9","author":"Erp","year":"2020","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.043_b0165","doi-asserted-by":"crossref","first-page":"e1006810","DOI":"10.1371\/journal.ppat.1006810","article-title":"Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection","volume":"14","author":"Schmidt","year":"2018","journal-title":"PLoS Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.043_b0170","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1172\/JCI115362","article-title":"Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice","volume":"88","author":"Graham","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2021.12.043_b0175","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/1521-4141(200208)32:8<2117::AID-IMMU2117>3.0.CO;2-C","article-title":"Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma","volume":"32","author":"Ostler","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2021.12.043_b0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1084\/jem.179.1.81","article-title":"Distinct types of lung disease caused by functional subsets of antiviral T cells","volume":"179","author":"Alwan","year":"1994","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.vaccine.2021.12.043_b0185","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm.3883","article-title":"The emerging role of resident memory T cells in protective immunity and inflammatory disease","volume":"21","author":"Park","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.12.043_b0190","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3389\/fimmu.2018.01770","article-title":"Armed and ready: transcriptional regulation of tissue-resident memory CD8 T Cells","volume":"9","author":"Behr","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.12.043_b0195","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nri.2015.3","article-title":"Tissue-resident memory T cells: local specialists in immune defence","volume":"16","author":"Mueller","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.043_b0200","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10224","article-title":"RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection","volume":"6","author":"Jozwik","year":"2015","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.vaccine.2021.12.043_b0205","doi-asserted-by":"crossref","first-page":"e0186854","DOI":"10.1371\/journal.pone.0186854","article-title":"Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus","volume":"12","author":"Sastry","year":"2017","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.043_b0210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/infdis\/jiw453","article-title":"A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant","volume":"215","author":"Langley","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.12.043_b0215","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/infdis\/jiy065","article-title":"Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results from 2 phase 2 trials","volume":"217","author":"Beran","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.12.043_b0220","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/infdis\/jiz395","article-title":"Immunogenicity and safety of 3 formulations of a respiratory syncytial virus candidate vaccine in nonpregnant women: a phase 2 randomized trial","volume":"220","author":"Schwarz","year":"2019","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21016510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21016510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:08:03Z","timestamp":1759403283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21016510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0264410X21016510"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}